Primary endpoint met, substantially reducing HAE attack symptoms
All secondary endpoints met
PHVS416 was well tolerated at all dose levels
Pharvaris to host a conference call today at 8:00 a.m. ET
Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced positive top-line data from the RAPIDe-1 Phase 2 clinical study, demonstrating statistically significant results of PHVS416 as an oral on-demand treatment for HAE attacks. Pharvaris plans to present data from the study at future medical meetings.
https://finance.yahoo.com/news/pharvaris-announces-positive-top-line-115000418.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.